Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR011 in Relapsed/Refractory CD19+ B-ALL
NCT03018093Phase 1Unknown
- Sponsor
- AbelZeta
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR011 in acute lymphoblastic leukemia (ALL), sponsored by AbelZeta. Primary endpoint: Dose-limiting toxicity at 30 days. Status: unknown.
02
Drugs
C-CAR011
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03018093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018093.